SRNE News and Press, Sorrento Therapeutics Inc. From 01/24/23

Summary Shares of Scilex could trade higher due to hedging pressure from large Sorrento short positions. Scilex's equity offering facilities, mean that the price could fall precipitously at any time via company dilution. Scilex's small free float, combined with the two drivers above...

Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single ascending dose (SAD) portion of the study with the doses from 300 mg to 2,000 mg in 32 healthy volunteers and the multiple ascending dose (MAD) portion of the study in...

4 Mistakes Penny Stocks Traders Should Avoid This Year Trading penny stocks can be a risky but potentially rewarding venture, and it’s important for traders to be aware of common mistakes that can cost them money. Here are some of the biggest mistakes that traders should avoid when it ...

Modified mRNA sequence of the Spike protein prevents cleavage of the expressed protein, which may potentially result in a cleaner safety profile. Pre-clinical data supporting the investigational new drug application has been published in Molecular Therapy Nucleic Acids, a Cell Press Journal (...

IMC-001, a PD-L1 monoclonal antibody selected from Sorrento’s G-MAB library, demonstrated impressive therapeutic effects in patients with heavily treated NK/T-cell lymphoma with a 60% objective response rate Achieved 100% complete remission in patients with an objective response rate ...

Topline safety and pharmacokinetic (PK) data from the Phase I single ascending dose (SAD)/multiple ascending dose (MAD) study of STI-1558 in 58 healthy volunteers in Australia are now available. The SAD portion of the study evaluated doses from 300 mg to 2,000 mg and the MAD portion evalu...

ATLANTA and SAN DIEGO, Nov. 13, 2022 (GLOBE NEWSWIRE) -- Sofusa®, a wholly-owned division of Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion titled “Empowering the Lymphatics: U...

Scilex plans to accelerate growth as a public company and advance further its non-opioid pain management therapeutic portfolio to transform the acute and chronic pain outpatient market Scilex will ring the Nasdaq opening bell at 9:30 a.m. ET on Friday, November 11, 2022. Watch the c...

Approximately 80% of the shareholders of Vickers present at the meeting of Vickers shareholders in connection with the business combination voted in favor of the business combination. Scliex’s shares of common stock and warrants are expected to begin trading on the Nasdaq Capit...

Summary Sorrento Therapeutics has been in the limelight for all the wrong reasons. Its R&D is just a byproduct of its business. Management compensation is very high. Sorrento Therapeutics ( SRNE ) is a commercial-stage company that, I would say, made a more o...